Biomarkers for Prognosis and Treatment Response in COVID-19 Patients

키워드

참고문헌 (81)

1. Bohn MK, "Molecular, serological, and biochemical diagnosis and monitoring of COVID-19: IFCC task force evaluation of the latest evidence", Clin Chem Lab Med, 58, pp.1037~1052 (2020)
2. Tang N, "Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia", J Thromb Haemost, 18, pp.844~847 (2020)
3. Lin L, "Hypothesis for potential pathogenesis of SARS-CoV-2 infection-a review of immune changes in patients with viral pneumonia", Emerg Microbes Infect, 9, pp.727~732 (2020)
4. Guterres A, "What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19?", Infect Genet Evol, 85, pp.104417~ (2020)
5. Chauhan N, "COVID-19: fighting the invisible enemy with microRNAs", Expert Rev Anti Infect Ther, 19, pp.137~145 (2021)
6. Xie J, "Association between hypoxemia and mortality in patients with COVID-19", Mayo Clin Proc, 95, pp.1138~1147 (2020)
7. Qin C, "Dysregulation of immune response in patients with coronavirus 2019 (COVID-19) in Wuhan, China", Clin Infect Dis, 71, pp.762~768 (2020)
8. Liu F, "Prognostic value of interleukin-6, C-reactive protein, and procalcitonin in patients with COVID-19", J Clin Virol, 127, pp.104370~ (2020)
9. Gong J, "Correlation analysis between disease severity and inflammation-related parameters in patients with COVID-19 pneumonia: a retrospective study", BMC Infect Dis, 20, pp.963~ (2020)
10. Luo X, "Prognostic value of C-reactive protein in patients with coronavirus 2019", Clin Infect Dis, 71, pp.2174~2179 (2020)
11. Kermali M, "The role of biomarkers in diagnosis of COVID-19–A systematic review", Life Sci, 254, pp.117788~ (2020)
12. Gao Y, "Diagnostic utility of clinical laboratory data determinations for patients with the severe COVID-19", J Med Virol, 92, pp.791~796 (2020)
13. Ahnach M, "C-reactive protein as an early predictor of COVID-19 severity", J Med Biochem, 39, pp.500~507 (2020)
14. Luo W, "Circulating levels of IL-2, IL-4, TNF-alpha, IFN-gamma, and C-reactive protein are not associated with severity of COVID-19 symptoms", J Med Virol, 93, pp.89~91 (2021)
15. He X, "The poor prognosis and influencing factors of high D-dimer levels for COVID-19 patients", Sci Rep, 11, pp.1830~ (2021)
16. Asakura H, "COVID-19-associated coagulopathy and disseminated intravascular coagulation", Int J Hematol, 113, pp.45~57 (2021)
17. Luo HC, "Characteristics of coagulation alteration in patients with COVID-19", Ann Hematol, 100, pp.45~52 (2021)
18. Villard O, "The plasmatic aldosterone and C-reactive protein levels, and the severity of Covid-19: the Dyhor-19 study", J Clin Med, 9, pp.2315~ (2020)
19. Yang M, "A retrospective study of the C-reactive protein to lymphocyte ratio and disease severity in 108 patients with early COVID-19 pneumonia from January to March 2020 in Wuhan, China", Med Sci Monit, 26, pp.e926393~ (2020)
20. Wang D, "Correlation analysis between disease severity and clinical and biochemical characteristics of 143 cases of COVID-19 in Wuhan, China: a descriptive study", BMC Infect Dis, 20, pp.519~ (2020)
21. Ali N, "Elevated level of C-reactive protein may be an early marker to predict risk for severity of COVID-19", J Med Virol, 92, pp.2409~2411 (2020)
22. Tan C, "C-reactive protein correlates with computed tomographic findings and predicts severe COVID-19 early", J Med Virol, 92, pp.856~862 (2020)
23. Li Q, "Eosinopenia and elevated C-reactive protein facilitate triage of COVID-19 patients in fever clinic: a retrospective case-control study", EClinicalMedicine, 23, pp.100375~ (2020)
24. Chen L, "Analysis of clinical features of 29 patients with 2019 novel coronavirus pneumonia", Zhonghua Jie He He Hu Xi Za Zhi, 43, pp.203~208 (2020)
25. Montesarchio V, "Outcomes and biomarker analyses among patients with COVID-19 treated with interleukin 6 (IL-6) receptor antagonist sarilumab at a single institution in Italy", J Immunother Cancer, 8, pp.e001089~ (2020)
26. Ponti G, "Biomarkers associated with COVID-19 disease progression", Crit Rev Clin Lab Sci, 57, pp.389~399 (2020)
27. Zhang C, "Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality", Int J Antimicrob Agents, 55, pp.105954~ (2020)
28. Xu XL, "Effective treatment of severe COVID-19 patients with tocilizumab", Proc Natl Acad Sci U S A, 117, pp.10970~10975 (2020)
29. Guan WJ, "Comorbidity and its impact on 1590 patients with COVID-19 in China: a nationwide analysis", Eur Respir J, 55, pp.2000547~ (2020)
30. Zhang G, "Clinical features and short-term outcomes of 221 patients with COVID-19 in Wuhan, China", J Clin Virol, 127, pp.104364~ (2020)
31. Chen TL, "Clinical characteristics and outcomes of older patients with coronavirus disease 2019 (COVID-19) in Wuhan, China: a single-centered, retrospective study", J Gerontol A Biol Sci Med Sci, 75, pp.1788~1795 (2020)
32. Sun D, "Clinical features of severe pediatric patients with coronavirus disease 2019 in Wuhan: a single center’s observational study", World J Pediatr, 16, pp.251~259 (2020)
33. Huang C, "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China", Lancet, 395, pp.497~506 (2020)
34. Akbari H, "The role of cytokine profile and lymphocyte subsets in the severity of coronavirus disease 2019 (COVID-19): a systematic review and meta-analysis", Life Sci, 258, pp.118167~ (2020)
35. Wu C, "Risk factors associated with acute respiratory distress syndrome and death in patients with coronavirus disease 2019 pneumonia in Wuhan, China", JAMA Intern Med, 180, pp.934~943 (2020)
36. Yip TTC, "Protein chip array profiling analysis in patients with severe acute respiratory syndrome identified serum amyloid A protein as a biomarker potentially useful in monitoring the extent of pneumonia", Clin Chem, 51, pp.47~55 (2005)
37. Tan L, "Lymphopenia predicts disease severity of COVID-19: a descriptive and predictive study", Signal Transduct Target Ther, 5, pp.1~3 (2020)
38. Chen N, "Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study", Lancet, 395, pp.507~513 (2020)
39. Liu T, "The role of interleukin-6 in monitoring severe case of coronavirus disease 2019", EMBO Mol Med, 12, pp.e12421~ (2020)
40. Coomes EA, "Interleukin-6 in Covid-19: a systematic review and meta-analysis", Review Rev Med Virol, 30, pp.1~9 (2020)
41. Perlman S, "Another decade, another coronavirus", N Engl J Med, 382, pp.760~762 (2020)
42. Han H, "Prominent changes in blood coagulation of patients with SARS-CoV-2 infection", Clin Chem Lab Med, 58, pp.1116~1120 (2020)
43. Zhang L, "D‐dimer levels on admission to predict in‐hospital mortality in patients with Covid‐19", J Thromb Haemost, 18, pp.1324~1329 (2020)
44. Frater JL, "COVID-19 and the clinical hematology laboratory", Int J Lab Hematol, 42(S1), pp.11~18 (2020)
45. Liu Y, "Association between platelet parameters and mortality in coronavirus disease 2019: retrospective cohort study", Platelets, 31, pp.490~496 (2020)
46. "Clinical findings of 35 cases with novel coronavirus pneumonia outside of Wuhan"[URL]
47. Guan WJ, "Clinical characteristics of coronavirus disease 2019 in China", N Engl J Med, 382, pp.1708~1720 (2020)
48. Xiong Y, "Clinical and high-resolution CT features of the COVID-19 infection: comparison of the initial and follow-up changes", Invest Radiol, 55, pp.332~339 (2020)
49. Mo P, "Clinical characteristics of refractory COVID-19 pneumonia in Wuhan, China", Clin Infect Dis, pp.ciaa270~ (2020)
50. Li H, "Serum amyloid A is a biomarker of severe coronavirus disease and poor prognosis", J Infect, 80, pp.646~655 (2020)
51. Zeng F, "Association of inflammatory markers with the severity of COVID-19: a meta-analysis", Int J Infect Dis, 96, pp.467~474 (2020)
52. Zhou F, "Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study", Lancet, 395, pp.1054~1062 (2020)
53. Shi S, "Association of cardiac injury with mortality in hospitalized patients with COVID-19 in Wuhan, China", JAMA Cardiol, 5, pp.802~810 (2020)
54. Aboughdir M, "Prognostic value of cardiovascular biomarkers in COVID-19: a review", Viruses, 12, pp.527~ (2020)
55. Tersalvi G, "Elevated troponin in patients with coronavirus disease 2019: possible mechanisms", J Card Fail, 26, pp.470~475 (2020)
56. Bansal M, "Cardiovascular disease and COVID-19", Diabetes Metab Syndr, 14, pp.247~250 (2020)
57. Wang D, "Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan, China", JAMA, 323, pp.1061~1069 (2020)
58. Vestjens SMT, "High-sensitivity cardiac troponin T predicts mortality after hospitalization for community-acquired pneumonia", Respirology, 22, pp.1000~1006 (2017)
59. Bessière F, "Prognostic value of troponins in sepsis: a meta-analysis", Intensive Care Med, 39, pp.1181~1189 (2013)
60. "Troponin and BNP use in COVID-19"[URL]
61. Chapman AR, "High-sensitivity cardiac troponin can be an ally in the fight against COVID-19", Circulation, 141, pp.1733~1735 (2020)
62. Tian S, "Characteristics of COVID-19 infection in Beijing", J Infect, 80, pp.401~406 (2020)
63. Cai Q, "COVID-19: abnormal liver function tests", J Hepatol, 73, pp.566~574 (2020)
64. Cheng Y, "Kidney disease is associated with in-hospital death of patients with COVID-19", Kidney Int, 97, pp.829~838 (2020)
65. Agnello L, "Presepsin and midregional Proadrenomedullin in pediatric oncologic patients with febrile neutropenia", Lab Med, 51, pp.585~591 (2020)
66. Bellia C, "Mid-regional pro-adrenomedullin predicts poor outcome in non-selected patients admitted to an intensive care unit", Clin Chem Lab Med, 57, pp.549~555 (2019)
67. Spoto S, "High value of mid-regional proadrenomedullin in COVID-19: a marker of widespread endothelial damage, disease severity and mortality", J Med Virol, 93, pp.2820~2827 (2020)
68. Agnello L, "Monocyte distribution width (MDW) as a screening tool for sepsis in the emergency department", Clin Chem Lab Med, 58, pp.1951~1957 (2020)
69. Agnello L, "Monocyte distribution width as a biomarker of sepsis in the intensive care unit: a pilot study", Ann Clin Biochem, 58, pp.70~73 (2021)
70. Agnello L, "Reference interval of monocyte distribution width (MDW) in healthy blood donors", Clin Chim Acta, 510, pp.272~277 (2020)
71. Ognibene A, "Elevated monocyte distribution width in COVID-19 patients: the contribution of the novel sepsis indicator", Clin Chim Acta, 509, pp.22~24 (2020)
72. Guterres A, "What is the potential function of microRNAs as biomarkers and therapeutic targets in COVID-19?", Infect Genet Evol, 85, pp.104417~ (2020)
73. Girardi E, "On the importance of host microRNAs during viral infection", Front Genet, 9, pp.439~ (2018)
74. Bartel DP, "MicroRNAs: genomics, biogenesis, mechanism, and function", Cell, 116, pp.281~297 (2004)
75. Khurshid Z, "Human saliva: non-invasive fluid for detecting novel coronavirus (2019-nCoV)", Int J Environ Res Public Health, 17, pp.22~25 (2020)
76. Tvarijonaviciute A, "Saliva as a non-invasive tool for assessment of metabolic and inflammatory biomarkers in children", Clin Nutr, 39, pp.2471~2478 (2020)
77. Ceron JJ, "Use of saliva for diagnosis and monitoring the SARS-CoV-2: a general perspective", J Clin Med, 9, pp.1491~ (2020)
78. Song Y, "A digital protein microarray for COVID-19 cytokine storm monitoring", Lab Chip, 21, pp.331~343 (2020)
79. Rissin DM, "Single-molecule enzyme-linked immunosorbent assay detects serum proteins at subfemtomolar concentrations", Nat Biotechnol, 28, pp.595~599 (2010)
80. Choi JR, "Development of point-of-care biosensors for COVID-19", Front Chem, 8, pp.517~ (2020)
81. Garg M, "Advancement in biosensors for inflammatory biomarkers of SARS-CoV-2 during 2019–2020", Biosens Bioelectron, 171, pp.112703~ (2021)

관련 논문AI추천